Skip to content
Peptigraph home

Cagrilintide vs Retatrutide: What the Research Shows

Cagrilintide and Retatrutide side by side: what they are, how they are regulated and what is still unknown.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
Amylin analogInvestigational (CagriSema component)CagrilintideInvestigational amylin analogue, not FDA-approved; a meta-analysis found cagrilintide monotherapy reduced body weight by a mean difference of -6.08%.[14]GLP-1 & metabolicGLP-1 / GIP / glucagon triple agonistInvestigational · phase 3RetatrutideInvestigational triple GIP, GLP-1 and glucagon receptor agonist, not FDA-approved; a phase 3 TRIUMPH trial reported mean weight change of -25.0% at the 12-mg dose versus -3.9% with placebo.[1]GLP-1 & metabolic
Quick verdict

Where the research points

Summary of studies, not a recommendation

Consider Cagrilintide if…

  • you are weighing an investigational option (no FDA-approved product): in its phase 2 trial, mean weight reductions were greater with all cagrilintide doses than with placebo[9]

Consider Retatrutide if…

  • you are weighing an investigational option (no FDA-approved product yet): the TRIUMPH trial reported mean weight change of -25.0% with the 12-mg dose versus -3.9% with placebo[1]
  • you want to know where approval stands: Lilly states it plans to submit a Biologics License Application to the FDA, a submission plan and not an approval[16]

What they have in common

  • Cagrilintide is prohibited by WADA at all times, in and out of competition (as a drug with no approval anywhere)[5]
  • Retatrutide is prohibited by WADA at all times, in and out of competition (as a drug with no approval anywhere)[5]
Neither is FDA approved for any use in people. Both are prohibited in tested sport (WADA). Status labels come from public FDA and WADA records; see the sources below.
Side by side

Spec comparison

Showing 7 of 12 fields where the two differ. Category, PCAC vote, Jul 2026, WADA, Evidence strength, Named in FDA warning letters, 2026 are the same or both unknown.

FieldCagrilintideRetatrutide
ClassAmylin analogGLP-1 / GIP / glucagon triple agonist
Also calledcagri, cagreta, GLP-3, LY3437943
FDA statusInvestigational (CagriSema component)Investigational · phase 3
Half-life159-195 h (with semaglutide 2.4 mg co-administered)subcutaneous · Lancet 2021, PMID 33894838approximately 6 dayssubcutaneous · Lancet 2022, PMID 36354040
Human studies we summarised5 human (5 randomized or controlled) of 8 summarised11 human (11 randomized or controlled) of 16 summarised
Typical study doses
Vial sizes sold2.5 mg, 5 mg, 10 mg5 mg, 10 mg, 12 mg, 15 mg, 20 mg, 24 mg, 30 mg, 36 mg, 40 mg, 50 mg, 60 mg

Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.

Taken together?

Cagrilintide and Retatrutide together

People also search for this pair as a stack. The stack page covers timing and interaction questions as they are sourced. Evidence for the combination: No studies tested these together (PubMed search: 22 results, 2 Oct 2026).

Open the stack page

An amylin analogue versus a triple agonist: what the trials measured

Cagrilintide is an analogue of natural amylin, a pancreatic hormone that induces satiety.[9]

Retatrutide is a triple-receptor agonist acting at the GIP, GLP-1 and glucagon receptors.[1]

Cagrilintide's phase 2 trial was a dose-finding design that compared several weekly doses with a daily liraglutide arm and with placebo.[9]

Its treatment period was 26 weeks, including a dose-escalation period of up to 6 weeks.[9]

At the top cagrilintide dose, weight loss was greater than with the liraglutide comparator, and the reported difference was statistically significant.[9]

Retatrutide's TRIUMPH-1 randomised 2339 adults with obesity.[1]

It ran for 80 weeks at retatrutide doses of 4 mg, 9 mg or 12 mg against placebo.[1]

Knee osteoarthritis pain and sleep apnea were assessed in subgroups of that trial.[1]

A meta-analysis covering 5425 participants found cagrilintide monotherapy lowered body weight by 6.08% and lowered blood pressure, with no meaningful HbA1c improvement.[14]

Safety, kinetics and status

In the phase 1b trial cagrilintide had a half-life of 159-195 h across doses of 0.16-4.5 mg.[6]

A thorough QT study in 105 healthy participants found no clinically relevant QTc prolongation after the last 4.5 mg cagrilintide dose.[8]

In the cagrilintide phase 1b trial, every dose was given in combination with once-weekly semaglutide 2.4 mg.[6]

Retatrutide has no FDA record: the Drugs@FDA search returned no matches.[17]

Cagrilintide has none either: its Drugs@FDA search also returned no matches.[18]

Common questions

Cagrilintide vs retatrutide: which causes more weight loss?

They have not been compared head to head. Retatrutide's phase 3 and cagrilintide's phase 2 trials differ in length and design, so the headline percentages are not comparable.[1]

Is cagrilintide the same as CagriSema?

No. CagriSema is the combination of cagrilintide with semaglutide, and the meta-analysis reports cagrilintide and CagriSema results separately.[14]

Are cagrilintide and retatrutide approved?

Neither appears in the FDA approvals database: the searches for both returned no matches.[18]

Sources

  1. 1Retatrutide phase 3 TRIUMPH-1 results publishedNEJM (PubMed 42814954) · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  2. 2FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  3. 3Eli Lilly sues six retatrutide sellersEli Lilly (press release) · 2026investor.lilly.comAccessed 2 Oct 2026
  4. 4Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
  5. 5World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  6. 6Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.Lancet (London, England) · 2021PMID 33894838Accessed 2 Oct 2026
  7. 7Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.Clinical pharmacokinetics · 2026PMID 42228334Accessed 2 Oct 2026
  8. 8Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants.Diabetes, obesity & metabolism · 2024PMID 39279639Accessed 2 Oct 2026
  9. 9Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.Lancet (London, England) · 2021PMID 34798060Accessed 2 Oct 2026
  10. 10LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.Lancet (London, England) · 2022PMID 36354040Accessed 2 Oct 2026
  11. 11Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.Diabetes, obesity & metabolism · 2026PMID 42608321Accessed 2 Oct 2026
  12. 12Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.The lancet. Diabetes & endocrinology · 2025PMID 40609566Accessed 2 Oct 2026
  13. 13PubMed search: (cagrilintide[tiab]) AND (retatrutide[tiab] OR LY3437943[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  14. 14Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.Annals of medicine and surgery (2012) · 2026PMID 42583410Accessed 2 Oct 2026
  15. 15Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.Lancet (London, England) · 2023PMID 37364590Accessed 11 Oct 2026
  16. 16Official web pageOfficial web page · web page
  17. 17Drugs@FDA (openFDA) search: active ingredient "retatrutide"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  18. 18Drugs@FDA (openFDA) search: active ingredient "cagrilintide"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026

Found an error? Report a correction.